文献速递细菌感染、耐药与抗菌药物

亚胺培南/雷利巴坦对中国肠杆菌科临床分离株的体外活性:SMART监测2015-2018

In Vitro Activity of Imipenem/Relebactam Against Enterobacteriaceae Isolates Obtained from Intra-abdominal, Respiratory Tract, and Urinary Tract Infections in China: Study for Monitoring Antimicrobial Resistance Trends (SMART), 2015-2018.
PubMed 文献 · Clin Infect Dis · 2020-01-01

研究收集2015-2018年中国7个地理区域22家医院的8781株肠杆菌科临床分离株,采用CLSI肉汤微量稀释法及折点检测药物敏感性,并按FDA指南评估亚胺培南/雷利巴坦(IMI/REL)活性。结果显示肠杆菌科对IMI/REL总体敏感率为95.2%,在腹腔感染、呼吸道感染和尿路感染分离株中分别为95.8%、91.4%和96.6%;IMI/REL使66.3%对亚胺培南不敏感的肠杆菌科恢复敏感性。

要点

  • 中国肠杆菌科临床分离株对IMI/REL总体敏感率95.2%,腹腔、呼吸道、尿路感染分离株分别为95.8%、91.4%、96.6%。
  • IMI/REL可使66.3%对亚胺培南不敏感的肠杆菌科恢复敏感性。
  • ICU与非ICU肠杆菌科分离株对黏菌素敏感率均为92.9%,对IMI/REL分别为90.7%与95.9%。

核心结论

  • 鉴于中国肠杆菌科分离株对IMI/REL体外敏感率高,应考虑将IMI/REL用于中国肠杆菌科感染的治疗,尤其对碳青霉烯类不敏感的分离株。

研究设计与样本

  • 2015-2018年从中国7个地理区域22家医院收集8781株肠杆菌科临床分离株。
  • 采用CLSI肉汤微量稀释法和折点检测抗菌药物敏感性,并按FDA指南评估IMI/REL活性。

主要发现

  • 最常见菌种为大肠埃希菌4676株(53.3%),其次为肺炎克雷伯菌2949株(33.6%)和阴沟肠杆菌542株(6.2%)。
  • 肠杆菌科分离株对IMI/REL总体敏感率为95.2%,腹腔感染、呼吸道感染和尿路感染分离株分别为95.8%、91.4%和96.6%。
  • ICU与非ICU肠杆菌科分离株对黏菌素敏感率均为92.9%,对IMI/REL分别为90.7%与95.9%,对阿米卡星分别为83.3%与92.3%。
  • IMI/REL使66.3%对亚胺培南不敏感的肠杆菌科恢复敏感性。

临床怎么用

  • 对碳青霉烯类不敏感的中国肠杆菌科感染,可考虑选用IMI/REL。
  • 腹腔感染、尿路感染和呼吸道感染分离株对IMI/REL体外敏感率均较高,可作为经验或目标治疗参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Considering the increasing incidence of carbapenem-resistant Enterobacteriaceae in China, this study aimed to establish the in vitro effectiveness of imipenem/relebactam (IMI/REL) on clinical Enterobacteriaceae isolates derived from intra-abdominal infections (IAIs), respiratory tract infections (RTIs), and urinary tract infections (UTIs) in China between 2015 and 2018. METHODS: In total, 8781 Enterobacteriaceae isolates from IAI, RTI, and UTI samples were collected from 22 hospitals across 7 geographic regions of China. Susceptibility to antimicrobial drugs was tested using the Clinical and Laboratory Standards Institute broth microdilution and breakpoints, and IMI/REL activity was assessed using United States Food and Drug Administration guidelines. RESULTS: In 2015-2018, the most frequently identified Enterobacteriaceae species was Escherichia coli (n = 4676 [53.3%]), followed by Klebsiella pneumoniae (n = 2949 [33.6%]) and Enterobacter cloacae (n = 542 [6.2%]). The Enterobacteriaceae isolates showed 95.2% overall susceptibility to IMI/REL, of which the susceptibility rates in isolates from IAI, RTI, and UTI were 95.8%, 91.4%, and 96.6%, respectively. Overall, the susceptibilities of both intensive care unit (ICU) and non-ICU Enterobacteriaceae isolates to colistin were 92.9%, followed by IMI/REL (90.7% [95.9%]) and amikacin (83.3% [92.3%]). In addition, IMI/REL restored 66.3% susceptibility in imipenem-nonsusceptible Enterobacteriaceae. CONCLUSIONS: Given their high in vitro susceptibility, Enterobacteriaceae infections in China should be considered for IMI/REL treatment, especially with isolates that are not susceptible to carbapenems.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yang Q, Zhang H, Yu Y, et al. In Vitro Activity of Imipenem/Relebactam Against Enterobacteriaceae Isolates Obtained from Intra-abdominal, Respiratory Tract, and Urinary Tract Infections in China: Study for Monitoring Antimicrobial Resistance Trends (SMART), 2015-2018. Clin Infect Dis. 2020. PMID: 33367580. doi:10.1093/cid/ciaa1519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。